New drug combo for platinum-resistant ovarian cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a new combination of drugs—QL1706 (which targets two immune checkpoints), nab-paclitaxel, and bevacizumab—for people with ovarian cancer that has stopped responding to platinum chemotherapy. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have ovarian, fallopian tube, or primary peritoneal cancer that is resistant to platinum chemotherapy (it got worse within 6 months of treatment).
- You are between 18 and 75 years old and are generally able to care for yourself (ECOG score 0 or 1).
- You have at least one tumor that can be measured on a scan (like a CT or MRI).
- Your kidney, liver, and blood cell counts are within acceptable ranges, as checked by blood and urine tests.
- You have not had immunotherapy that blocks both PD-1 and CTLA-4, and you have not had radiation to your abdomen or pelvis before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of a new immunotherapy drug (QL1706), chemotherapy, and a targeted therapy (anlotinib) for ovarian cancer that has come back after standard platinum treatment. The goal is to see if this triple therapy can shrink tumors or slow the cancer's return.
This trial tests a combination of three drugs (etoposide capsules, bevacizumab, and an immunotherapy pair) for ovarian cancer that no longer responds to standard platinum chemotherapy. It aims to find a new treatment option for women with resistant or refractory disease.
This trial tests a new combination of drugs (trastuzumab rezetecan and carboplatin, with or without bevacizumab) against standard chemotherapy for women with recurrent ovarian, fallopian tube, or primary peritoneal cancer. It’s for those who have already had platinum-based chemo and a PARP inhibitor, and whose cancer came back after a treatment-free interval of at least 6 months.
This trial tests adding a new immunotherapy drug (QL1706) to standard chemotherapy plus bevacizumab for people with colorectal cancer that has spread and hasn't been treated yet. It aims to see if the combination works better than standard treatment alone.
This trial tests a combination of an immunotherapy drug (QL1706) and a targeted therapy (bevacizumab) for women with newly diagnosed advanced ovarian clear cell carcinoma. The goal is to see if this combination works better than standard treatment after surgery.
This trial tests a new combination therapy (SYS6041 plus another drug) for women with recurrent ovarian cancer. It is for those whose cancer has come back after platinum chemotherapy, and who have not had too many previous treatments. The goal is to see if the combination can shrink tumors or slow disease progression.
Hear when a new Platinum-resistant Recurrent Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.